Barclays
IMDX

Barclays’s Insight Molecular Diagnostics IMDX Stock Holding History

Barclays’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed – – 5041
2022
Q2 		$0 Sell
2
-486
-100% -$11.1K ﹤0.01% 5191
2022
Q1 		$14K Sell
488
-3,164
-87% -$101K ﹤0.01% 4532
2021
Q4 		$158K Buy
3,652
+2,422
+197% +$139K ﹤0.01% 3628
2021
Q3 		$87K Buy
1,230
+721
+142% +$66.3K ﹤0.01% 3964
2021
Q2 		$58K Sell
509
-4,974
-91% -$486K ﹤0.01% 4068
2021
Q1 		$569K Buy
5,483
+1,964
+56% +$186K ﹤0.01% 3108
2020
Q4 		$168K Sell
3,519
-418
-11% -$15.3K ﹤0.01% 3864
2020
Q3 		$110K Sell
3,937
-2,255
-36% -$64.7K ﹤0.01% 4201
2020
Q2 		$237K Sell
6,192
-2,681
-30% -$138K ﹤0.01% 3934
2020
Q1 		$434K Buy
8,873
+336
+4% +$16.5K ﹤0.01% 3703
2019
Q4 		$384K Buy
8,537
+8,007
+1,511% +$289K ﹤0.01% 4517
2019
Q3 		$22K Sell
530
-163
-24% -$6.41K ﹤0.01% 6192
2019
Q2 		$35K Sell
693
-216
-24% -$18K ﹤0.01% 6237
2019
Q1 		$72K Buy
+909
New +$58.6K ﹤0.01% 5621
2018
Q4 		– Hold
0
– – – 7214
2018
Q3 		– Hold
0
– – – 7314
2018
Q2 		– Sell
-40
Closed -$1.97K – 7184
2018
Q1 		$2K Buy
40
+9
+29% +$595 ﹤0.01% 6906
2017
Q4 		$3K Buy
31
+26
+520% +$2.93K ﹤0.01% 6735
2017
Q3 		$1K Buy
+5
New +$524 ﹤0.01% 6760
2017
Q2 		– Sell
-53
Closed -$6.03K – 6841
2017
Q1 		$6K Buy
+53
New +$6.12K ﹤0.01% 6236
2016
Q4 		– Hold
0
– – – 6763
2016
Q3 		– Sell
-15
Closed -$1.21K – 6737
2016
Q2 		$1K Buy
+15
New +$1.4K ﹤0.01% 6134
2016
Q1 		– Hold
0
– – – 6358

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

Barclays's IMDX Position: Q3 2022 in Review

Barclays sold out of Insight Molecular Diagnostics (IMDX) in Q3 2022, closing a stake of 2 shares.

Barclays first reported a position in IMDX in Q2 2016 and held it in 19 quarters. The position peaked at $569K in Q1 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

  • Barclays reported no remaining Insight Molecular Diagnostics position as of Q3 2022 after selling out during the quarter.
  • Barclays sold 2 Insight Molecular Diagnostics shares in Q3 2022.
  • Barclays first reported a position in Insight Molecular Diagnostics in Q2 2016 and held it in 19 quarters.
  • Barclays's Insight Molecular Diagnostics position peaked at $569K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.